HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vasostatin increases oxygenation of B16-F10 melanoma tumors and raises therapeutic efficacy of cyclophosphamide.

Abstract
One of the preconditions of effective anticancer therapy is efficient transfer of the therapeutic agent (chemotherapeutic) to tumor cells. Fundamental barriers making drug delivery and action difficult include underoxygenation, elevated interstitial pressure, poor and abnormal tumor blood vascular network and acidic tumor milieu. In this study we aimed at developing an optimized scheme of administering a combination of an angiogenesis-inhibiting drug (vasostatin) and a chemotherapeutic (cyclophosphamide) in the therapeutic treatment of mice bearing experimental B16-F10 melanoma tumors. We report that the strongest tumor growth inhibition was observed in mice that received two, three or four vasostatin doses in combination with one injection of cyclophosphamide (i.e., V2 + CTX, V3 + CTX or V4 + CTX schemes). Double administration of vasostatin increases oxygenation of B16-F10 tumors. On the other hand, its five-fold administration lowers tumor oxygenation, breaks down tumor vascular network (increasing hypoxia) and leads in consequence to death of cancer cells and appearance of necrotic areas in the tumor. A decreased cyclophosphamide dose in combination with two doses of vasostatin (V2 + CTX scheme) inhibits tumor growth similarly to a larger dose of cyclophosphamide alone.
AuthorsTomasz Cichoń, Magdalena Jarosz, Ryszard Smolarczyk, Barbara Ogórek, Sybilla Matuszczak, Marek Wagner, Iwona Mitrus, Aleksander Sochanik, Joanna Jazowiecka-Rakus, Stanisław Szala
JournalActa biochimica Polonica (Acta Biochim Pol) Vol. 59 Issue 3 Pg. 377-81 ( 2012) ISSN: 1734-154X [Electronic] Poland
PMID22946026 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Calreticulin
  • HMGB1 Protein
  • Peptide Fragments
  • vasostatin
  • Cyclophosphamide
  • Oxygen
Topics
  • Animals
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (standards, therapeutic use)
  • Calreticulin (administration & dosage, therapeutic use)
  • Cell Hypoxia
  • Cell Line, Tumor
  • Cyclophosphamide (administration & dosage, therapeutic use)
  • Female
  • HMGB1 Protein (metabolism)
  • Immunohistochemistry
  • Melanoma, Experimental (drug therapy, metabolism)
  • Mice
  • Mice, Inbred C57BL
  • Oxygen (metabolism)
  • Peptide Fragments (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: